Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Gynecologic 1

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 13Urinary Bladder Neoplasms 11Ovarian Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 5Colorectal Neoplasms 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Recurrence 2Rectal Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Gallbladder Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Oxaliplatin 9Leucovorin 8Fluorouracil 8Bevacizumab 6Cetuximab 5Specimen Handling 4fludarabine 3Pemetrexed 3Nivolumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3pembrolizumab 2encorafenib 2dehydroftorafur 2aldesleukin 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Folfox protocol 2Disulfides 2Cisplatin 2Celecoxib 2Carboplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sapanisertib 1repotrectinib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × Gemcitabine × 30 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Pfizer

Phase 1 Terminated
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡